VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EORTC CLTF 2021 | Brentuximab vedotin for CTCL

Christoph Blazejak, MD, Department of Dermatology HELIOS Klinikum Krefeld, Krefeld, Germany, outlines the use of the CD30-targeting antibody-drug conjugate brentuximab vedotin in the treatment of cutaneous T-cell lymphoma (CTCL), highlighting a response rate of around 60% and a median progression-free survival of around a year. Dr Blazejak also comments on the safety profile of brentuximab vedotin and on the impact of its approval on the CTCL treatment landscape. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter